GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.92 USD | -0.82% |
|
-0.43% | -19.86% |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | Other Pharmaceuticals | -0.82% | -0.43% | -19.86% | -18.60% | -2.23% | 81.63B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- GILD Stock
- Charts Gilead Sciences, Inc.
- Comparison Chart